Thesis
Approved XPO1 inhibitor files for myelofibrosis on one co-primary met, one missed, with runway expiring at filing — approval path and survival both unresolved
Karyopharm's selinexor (Xpovio), already approved in myeloma, is pursuing myelofibrosis via accelerated approval after SENTRY met the SVR35 spleen endpoint but missed the symptom co-primary, a split result the FDA must accept as approvable on a surrogate alone. The thesis resolves on whether FDA grants accelerated approval on that single-arm surrogate basis and whether a strategic transaction or financing closes before cash runs out in Q3 2026. The endometrial cancer program just failed its Phase 3 primary endpoint, removing a second revenue path and narrowing everything to the myelofibrosis sNDA.
Focus
FDA Engagement on SENTRY sNDA Filing Plan
August 2026
Bull
A productive FDA engagement results in alignment on the data package needed to support the accelerated approval sNDA, the filing proceeds in August 2026 as planned, and the agency accepts the submission — validating SVR35 as a basis for approval despite the missed Abs-TSS co-primary endpoint. A Prescription Drug User Fee Act action date would provide a defined path to selinexor's first approval in myelofibrosis, likely enabling a parallel financing transaction or strategic deal that extends the runway through a potential approval decision.
Bear
FDA's request for further discussion could signal substantive concerns about the adequacy of the single met co-primary endpoint as a basis for accelerated approval, potentially delaying the filing beyond August 2026 or resulting in a complete response or refusal to file — all scenarios that would exhaust the company's liquidity before a decision is reached. Additionally, the missed Abs-TSS endpoint and an overall survival signal that was nominally positive but not formally powered as a primary endpoint may give the agency grounds to request additional data or a confirmatory trial commitment that the company cannot finance.
Unlock the full thesis for KPTI.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.